Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma

NCT03116555 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.

NCT NCT03116555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03116555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma
Lead sponsor
China Medical University, China
Phase
Phase 2
Overall status
Unknown status
Start date
April 5, 2017
Completion date
September 30, 2020
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric adenocarcinoma